1. Diagnostic criteria: IDH wild-type GBM is one of the core indicators for diagnosing IDH wild-type GBM according to the WHO.2. Treatment stratification: It has the potential to serve as a treatment stratification biomarker. Studies have shown that tumors harboring this mutation may require more aggressive surgical resection and TMZ chemotherapy strategies. Here, IDH1 is linked to glioblastoma.